Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of anatolian Society of medical oncology (ASMO)

Basit Öğe Kaydı
dc.contributor.authorAydın, Dinçer
dc.contributor.authorŞendur, Mehmet Ali
dc.contributor.authorKefeli, Umut
dc.contributor.authorÜnal, Olçun Umut
dc.contributor.authorTaştekin, Didem
dc.contributor.authorAkyol, Murat
dc.contributor.authorTanrıkulu, Eda
dc.contributor.authorÇiltaş, Aydin
dc.contributor.authorUstaalioğlu Bala, Başak
dc.contributor.authorDede Şener, Didem
dc.contributor.authorEsbağ, Onur
dc.contributor.authorİnal, Ali
dc.contributor.authorBilir, Cemil
dc.contributor.authorBilici, Ahmet
dc.contributor.authorHarputlu, Hakan
dc.contributor.authorBerk, Veli
dc.contributor.authorSevinç, Alper
dc.contributor.authorÖzdemir Yıldırım, Nuriye
dc.contributor.authorYıldırım, Emre
dc.contributor.authorSonkaya, Alper
dc.contributor.authorUstaoğlu, Mehmet Ali
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:57:29Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:57:29Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000388782200027
dc.descriptionPubMed ID: 27837629
dc.description.abstractPurpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Methods: Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Results: Of the 71 patients, 42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow-up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=11), cisplatin-5-fluoroura-cil/5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 months, respectively, while median OS was 15, 16, 15 and 11 months, respectively. No significant differences between chemotherapy groups were noticed in terms of PFS and OS. Univariate analysis revealed that chemotherapy administration, de novo metastatic disease, ECOG PS 0 and 1, and overall response to therapy were significantly related to improved outcome. Only overall response to treatment was found to be significantly prognostic in multivariate analysis (p = 0.001). Conclusions: In this study, overall response to chemotherapy emerged as the single significant prognostic factor for advanced SBAs. Platin and irinotecan based regimens achieved similar survival outcomes in advanced SBA patients.
dc.identifier.citationAydın, D., Şendur, M. A., Kefeli, U., Ünal, O. U., Taştekin, D., Akyol, M. ... Gümüş, M. (2016). Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of anatolian Society of medical oncology (ASMO). Journal Of Buon, 21(5), 1242-1249.
dc.identifier.endpage1249
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue5
dc.identifier.scopusqualityQ3
dc.identifier.startpage1242
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2987
dc.identifier.volume21
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherImprimatur Publications
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdvanced
dc.subjectChemotherapy
dc.subjectPrognostic Factors
dc.subjectSmall Bowel Adenocarcinoma
dc.titleEvaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of anatolian Society of medical oncology (ASMO)
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilici-Ahmet 2016.pdf
Boyut:
272.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu